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Abstract. Worldwide, the incidence of oral tongue cancer is on the rise, adding to the existing burden due to prevailing low
survival and high recurrence rates. This study uses high-throughput expression profiling to identify candidate markers of
resistance/response in patients with oral tongue cancer. Analysis of primary and post-treatment samples (12 tumor and 8 normal)
by the Affymetrix platform (HGU133 plus 2) identified 119 genes as differentially regulated in recurrent tumors. The study groups
had distinct profiles, with induction of immune response and apoptotic pathways in the non-recurrent and metastatic/invasiveness
pathways in the recurrent group. Validation was carried out in tissues by Quantitative Real-Time PCR (QPCR) (n = 30) and
immunohistochemistry (IHC) (n = 35) and in saliva by QPCR (n = 37). The markers, COL5A1, HBB, IGLA and CTSC
individually and COL5A1 and HBB in combination had the best predictive power for treatment response in the patients. A subset
of markers identified (COL5A1, ABCG1, MMP1, IL8, FN1) could be detected in the saliva of patients with oral cancers with their
combined sensitivity and specificity being 0.65 and 0.87 respectively. The study thus emphasizes the extreme prognostic value
of exploring markers of treatment resistance that are expressed in both tissue and saliva.
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1. Introduction
Among various sub-sites of oral cancer, carcinoma
of the tongue poses a grave health concern. The inci-
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dence rate of tongue carcinoma is on the rise, up to 8
per annumper 100, 000 [1]. There is also a higher loco-
regional failure rate as compared to other oral cavity
sub-sites [2,3]. High-throughput genomic, transcrip-
tomic and proteomic studies provide an opportunity to
evaluate a large number of novel molecular markers
with prognostic significance [4,5]. It would be advanta-
geous if these biomarkers can be isolated in accessible
bodyfluids, in order to attainwider clinical utility. Sali-
va is currently emerging as a promising, non-invasive
means for detection of molecular indicators of disease
conditions [6,7]. In this context, studies reporting dif-
ferential patterns of transcriptome and proteome in sali-
va from normal controls and oral cancer patients [8–11]
and between premalignant and malignant lesions [12]
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gain significance. The molecular markers identified by
global expression studies, if detected and validated in
the saliva of oral cancer patients, would establish an
easy means of prognosis and can hence, further their
use in clinical application.
This study primarily aims to establish a molecular
signature specific to resistance and/or response to stan-
dard treatment for oral tongue squamous cell carcino-
ma. As a secondary objective, a subset of the biomark-
ers was further tested in saliva of oral cancer patients
to determine their efficacy in diagnosis and prognosis.
2. Patients and methods
2.1. Patient details and sample collection
The tissue samples were collected from patients un-
dergoing surgical treatment after obtaining Institution-
al Review Board approval and written informed con-
sent. The samples subjected to microarray analysis
were collected in RNA later (Ambion, Austin, USA),
while the samples for validationwere either snap frozen
or collected in RNA later and archived at −80◦C. The
clinical characteristics of the patients were obtained
from the electronic medical records maintained at the
tertiary care cancer center. The sample sets were
grouped into three categories: Group I (Pre-treatment,
non-recurrent), which included pre-treatment tissues
from patients who remained disease-free after stan-
dard treatment (surgery and adjuvant chemo radiation);
Group II (Pre-treatment resistant/recurrent) included
pre-treatment tissues from those who recurred during
a 2-year follow up period; Group III (post-treatment
recurrent; standard treatment) included recurrent tissue
from patients with the recurrent disease. Group I &
III were analyzed by micro array, while the validation
was carried out in all the three groups. The adjacent
mucosal tissue was collected 2 cm away from the tu-
mor and confirmed as histologically negative for ma-
lignancy. Normal oral mucosa was also collected from
non-diseased controls (age and risk factor matched) af-
ter written informed consent. Saliva samples were col-
lected from healthy volunteers and previously untreat-
ed patients diagnosed with oral cancer (Stage I/II), af-
ter informed written consent. Unstimulated saliva was
collected and mixed with RNAlater (Ambion, Austin
USA) and stored at −80◦C.
2.2. RNA isolation, labeling of cRNA and
hybridization
Total RNA was isolated using the Qiagen RNeasy
Kit (Qiagen, CA, US) and the samples that qualified
through standard quality control criteria were select-
ed for microarray. 100–200 ng of RNA was taken
and biotinylated cRNA was prepared using the Two-
cycle labeling Kit protocol (Affymetrix, CA, USA).
The labeled cRNA was purified by the Genechip sam-
ple cleanup module (Qiagen, CA, US), fragmented and
20 µg hybridized to HGU133 plus 2 arrays (54,675
probes) using standard Affymetrix protocols. The hy-
bridized chips were washed, stained and scanned by
the Affymetrix Fluidics Station and Genechip Scanner
3000 using prescribed protocols.
2.3. Microarray analysis
The preliminary analysis to ascertain the internal
controls and the hybridization efficiency was carried
out using the Gene Chip Operating Software (GCOS)
and Microarray Suite (MAS 5, Affymetrix, CA, USA).
The CEL files were extracted and imported into Gene-
Spring 7.2 (Agilent Technologies, CA, USA) software
package for analysis. Raw image datawere background
corrected, normalized and summarized into probe set
expression values using Robust Microarray Analysis
(RMA) algorithm [13]. For inter-array comparisons,
data from each chip was normalized to 50% of the mea-
surements taken from that chip (measurements of <
0.01 were set to 0.01). Probe sets that were not reliably
detectedwere removed, byfiltering out thosewhose ex-
pression level was not > 50 and confidence p-values <
0.05, in at least 20% of the samples. To identify genes
differentially expressed, both in the non-recurrent and
recurrent tongue cancers as compared to adjacent mu-
cosal samples, the remaining genes were subjected to
Welch’s t-test, not assuming variances equal, at p <
0.05 and furthered filtered for fold change >1.5. A
subset of genes, identified by the analysis, was selected
for further validation.
Ingenuity Pathway Analysis was carried out to iden-
tify significant functions, signaling pathways and net-
works (Ingenuity Systems Inc. CA, USA) at the default
core analysis and core comparison platforms. Fishers’
exact test was used to identify the statistically signifi-
cant functions/pathways. The differentially expressed
genes were hierarchically clustered using Multi Exper-
iment Viewer, v 4.5 (MeV ) (TM4 Microarray Software
Suite, The Institute of Genomic Research (TIGR)) [14]
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Table 1
Primers used for quantitative PCR
S No Gene Primer sequence (5’-3’) Amplicon size (bp)
1 MMP1 F: ACACATGGTGTGAGTCC
R: TGGCCTATATGAATCCATAAGC
226
2 EMP1 F: TGGGGAGTTGTTATGCC
R: GCACTAAGACAGCCTTCT
214
3 ABCG1 F: CAGGAAGATTAGACACTGTGG
R: GAAAGGGGAATGGAGAGAAGA
177
4 COL5A1 F:CACAACTTGCCTGATGGAATAACA
R: GCAGGGTACAGCTGCTTGGT
134
5 IGLA F: GAGCCTGACGCCTGAGCA
R: AGGGAGAAGGGCTTGATGC
203
6 HBB F: GTGCATCTGACTCCTGAG
R: CCCAAAGGACTCAAAGAAC
138
7 CTSC F: CCTATCTTGACCTGCTGG
R: GCCAGAATTGCCAAGGTC
155
8 CCL18 F: CTGCCTCGTCTATACCTC
R: CACTTCTTATTGGGGTCAG
141
9 FN1 F: CAGACCCAGCTTAGAGT
R: CATCTTGGTTGGCTGC
247
10 FAPA F: ATGCAAGCCTGTATCAGA
R: ACACTGTGTCCAAAGC
231
11 SERPINH2 F: CCTGGGCCATAGTCATT
R: GGTGTTTTAGTGTCAGAAGAG
148
12 IL8 F: GAGGGTTGTGGAGAAGTTTTTG
R: CTGGCATCTTCACTGATTCTTG
88
13 IL1B F: GTGCTGAATGTGGACTCAATCC
R: ACCCTAAGGCAGGCAGTTG
120
14 GAPDH F: TCACCAGGGCTGCTTTTAACTC
R: ATGACAAGCTTCCCGTTCTCAG
150
with the Euclidean distance measurement and p values
were calculated after application of the non-parametric
Wilcoxon-Mann Whitney test (p < 0.5). Furthermore,
K-means clustering (K = 10; Euclidean distance) was
carried out to identify a sub-set of genes that would
clearly differentiate the groups under study.
2.4. Validation of the microarray data in tissue and
saliva samples by Quantitative PCR
RNA was isolated from tissues using Tri Reagent
(Sigma Aldrich, MO, USA), first strand synthesis was
done using MMLV Reverse transcriptase (Ambion,
Austin, USA) and Quantitative Real Time PCR (QRT
PCR) by the Power Syber Green kit (Applied Biosys-
tems, CA, USA) in an ABI 7300 Cycler (Applied
Biosystems, CA, USA). The expression levels of the
genes selected for validation (MMP1, EMP1, ABCG1,
COL5A1, IgLA, HBB, CTSC and CCL18) (Table 1) was
assessed by QRT PCR using the relative quantification
(ΔΔCT) method [15]. Expression was normalized us-
ing the endogenous control (GAPDH) and normal oral
mucosal tissues were used as the calibrator. Melting
curve analysis was done to ensure the specificity of the
product obtained.
Unstimulated saliva collected from patients/controls
was mixed with RNAlater; subsequently the samples
were centrifuged at 14,000 rpm for 20 minutes at 4◦C.
RNA was isolated from the salivary supernatant us-
ing the Qiagen Viral RNA Kit (Qiagen, CA, US). The
samples were assessed for their integrity using the ex-
pression of the endogenous control (GAPDH) by Re-
verse Transcription PCR (RT-PCR) as a criterion. A
subset of 10 candidate markers (MMP1, FN1, FAPA,
SERPINH2, IL8, IL1B, IgLA, ABCG1, COL5A1,HBB),
selected from this study and a previous microarray
study [16], were tested for their expression in saliva by
QRT PCR. The fold levels of expression were calcu-
lated using the ΔΔCT method, with the GAPDH ex-
pression used as the endogenous reference and the sali-
va samples from healthy volunteers as the calibrator.
The detection of one or more markers in the samples
was considered as ‘test positive = 1’ while absence of
any of the markers was considered ‘test negative = 0’.
The combined test result in the binary input format was
used for the statistical analysis. The expression patterns
were correlated to the disease status of the patients to
ascertain their clinical relevance.
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Table 2
Clinical characteristics of patients
Study Sample Med Risk habits# Med Med DFS
size age With Without follow up (months)
(Years) Risk Risk (months)
Microarray Set 12 54.5 6 6 47
Study Groups
Group I 6T, 4N* 43 3 3 48 −
Group III 6T, 4N 58 3 3 46 5.5
Validation Set 65 55.5 31 22 23.5
Study Groups
Group I 34 60 19 9 27
Group II 19 56 6 10 23.5 12
Group III 12 48 6 3 20.5 4
QRT 30 57 14 9 23
Group I 14 58 7 3 22 −
Group II 8 58 3 4 23 11
Group III 8 50 4 2 21.5 3.5
IHC 35 56 20 13 30
Group I 20 60 13 6 35 −
Group II 11 49 4 6 28 16.5
Group III 4 48 3 1 16.5 13
Saliva 37 51 11 14
Normal 12 52 4 6 −
T1/T2 25 50 7 8 18
* T: Tumor; N: Normal.
# Risk factor details provided for patients wherever information is available.
2.5. Immunohistochemical analysis
The protein expression of two genes (COL5A1 and
HBB), validated by QRT PCR was profiled in the tissue
sections of a different cohort of patients with tongue
cancer. The sections were deparaffinized and IHC car-
ried out according to standard protocols. The antibod-
ies were used in dilutions of 1:50 for both COL5A1
(sc133162; Santacruz Biotechnology, Santacruz, CA,
USA) and HBB (H4890; Sigma Aldrich,USA). The
sections were microwaved for antigen retrieval and
the staining detected by Dako REALTM EnVisionTM
kit (Dako Corporation, Carpenteria, CA, USA). The
sections were counterstained using haematoxylin and
scanned at low and high power to identify areas of even
staining and percentage of positive cells. The grades
of positivity were scored as follows; negative (< 1%),
grade I (1–10%), grade II (10–30%), III (30–60%) and
IV (> 60%). The intensity of staining was also graded
as mild, moderate and intense. The expression in the
normal oral mucosal tissues was used as control.
ReceiverOperatingCharacteristic (ROC) curve anal-
yseswere carried out by SPSS19 (IBM) andMedCalc
v 11.6.0.0 for the QPCR and IHC results. Area under
the curve was computed via numerical integration of
the ROC curves. The biomarkers, individually or in
combination, with the largest Area under Curve (AUC)
were identified to have the maximum predictive pow-
er for disease recurrence. Multiple regression analysis
was also carried out by the stepwise method to identify
the predictive value of the marker combinations.
3. Results
3.1. Patient characteristics
The microarray study included 20 tissue samples col-
lected from 12 patients, the study groups each included
6 tumor and 4 adjacent normal samples from patients of
Group I (Pre-treatment, non-recurrent) [median follow
up: 48 months (range 26–49 months)] and from Group
III (post-treatment, recurrent) respectively. The medi-
an age of the patients was 54.5 years (range 35–66);
10 patients were male and 2 were female. The detailed
characteristics of the patients are given in the Table 2.
The validation set included 65 patients diagnosed
with oral tongue cancer with a median follow up
of 23.5 months (range 11–49 months). Thirty pa-
tients were validated by QPCR (median follow up:
23 months, range: 11–42); 14 classified as Group
I (Pre-treatment non-recurrent), 8 as Group II (Pre-
treatment resistant/recurrent) (medianDFS: 11months)
and 8 as Group III (post-treatment recurrent) (medi-
an DFS: 3.5 months; range 2–7 months). Among
the 35 patients analyzed by IHC (median follow up:
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Table 3
Subset of the significant genes obtained in Non-recurrent and Recurrent
Non recurrent T vs N
Sl Affymetrix Gene Fold p Fold p
No ID symbol (NR/Normal) (NR/Normal) (R/Normal) (R/Normal)
1 204475 at MMP1 255.50 0.00012 74.50 0.00519
2 213139 at SNAI2 5.81 0.00014 2.81 0.0222
3 202458 at PRSS23 8.77 0.000186 4.53 0.0205
4 205828 at MMP3 35.40 0.000288 26.15 0.0141
5 205680 at MMP10 29.51 0.00102 23.70 0.0151
6 222108 at AMIGO2 5.25 0.00224 3.27 0.024
7 201976 s at MYO10 3.96 0.00396 2.21 0.0333
8 203936 s at MMP9 13.60 0.00438 8.39 0.0206
9 225681 at CTHRC1 16.01 0.00454 9.96 0.0378
10 225646 at CTSC 7.17 0.0058 4.66 0.0319
Recurrent T vs N
Sl Affymetrix Gene p Fold p Fold
No ID Symbol (R/Normal) (R/Normal) (NR/Normal) (NR/Normal)
1 204567 s at ABCG1 3.83E-05 6.71 0.00166 3.78
2 205479 s at PLAU 0.00409 7.66 0.00268 4.95
3 203562 at FEZ1 0.00837 6.14 0.0360 3.20
4 225285 at BCAT1 0.0196 6.16 0.0265 3.98
5 212488 at COL5A1 0.0197 7.18 0.0117 5.88
6 205959 at MMP13 0.0205 25.45 0.0313 10.91
7 202998 s at LOXL2 0.0206 5.31 0.0452 3.69
8 214297 at CSPG4 0.0249 5.44 0.0144 4.18
9 214329 x at TNFSF10 0.0303 4.09 0.0312 2.96
10 202688 at TNFSF10 0.0360 3.96 0.0141 2.31
30 months; range: 11–49), 20 were classified into
Group I, 11 into Group II [median DFS: 16.5 months;
range 8–28 months) and 4 into Group III (median DFS:
13 months; range: 2–14 months) (Table 2). Normal
oral mucosa from 5 non-diseased subjects was used as
control in both the experiments.
Validation was also carried out in 37 saliva samples,
12 controls (median age: 52 years, range 32–81) and 25
patients diagnosedwith early stage (T1/T2) oral tongue
cancer (median age: 50 years, range: 31–82 years).
The median follow up of the patients was 18 months
(range: 10–36 months) (Table 2). Among the T1/T2
patients, 3 showed nodal recurrences and one developed
distant metastasis.
3.2. Gene expression profiles that distinguish
recurrent and non recurrent tongue cancer
Supervised analysis was carried out on the expres-
sion profiles obtained from the Affymetrix HGU133
plus 2 arrays. Samples were grouped into Normal/ Tu-
mor, recurrent and non-recurrent for analytical pur-
pose. Hundred and ten genes were differentially regu-
lated in all the tumor samples (p < 0.05), 212 in non-
recurrent tumors (p < 0.005) and 112 in recurrent tu-
mors (p 0.01) (Supplementary data, Tables S1, S2,
S3).
The statistically significant subset of differential-
ly expressed genes in recurrent tongue cancer include
ABCG1, PLAU, COL5A1, FEZ1, while MMP1, 3, 10,
SNAI2, PRSS23 were up regulated in non-recurrent
group (Table 3). A noticeable feature was the repres-
sion of the hemoglobin genes (HBB, HBA1, HBA2)
in the recurrent samples and the induction of immune
response genes (IgLA, IgKC) in the non-recurrent set.
(Supplementary data, Tables S2 & S3). The significant
functions identified in non-recurrent subset (Ingenuity
Pathway Analysis, Ingenuity Systems Inc. CA, USA)
were cancer and cell death along with protein degra-
dation/synthesis. Recurrent sample set showed con-
nective tissue disorders, molecular transport and tis-
sue morphology as significant from among the major
functions identified (Supplementary Table S4).
The statistically significant lists of genes obtained
(p < 0.05) were clustered using hierarchical clustering
(HC) methods. The recurrent normal and tumor sam-
ples were classified by 261 probe sets (Fig. 1A); while a
subset of 92 probes classified the tumor samples into re-
sistant/responsive groups (Fig. 1B). K-means cluster-
ing (KMC) revealed significant clusters which includ-
ed the immune response genes induced (IGHA1, IGLA,
IGKC) in non-recurrent tumors and HBB/HBA1 cluster
repressed in the recurrent tumor samples (Fig. 1C & D).
Hierarchical clustering of the adjacent mucosal sam-
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Fig. 1. Hierarchical and K-means clustering of differentially expressed genes in recurrent tongue cancer. Clustering analysis was done using
MeV (TIGR) after application of Wilcoxon Mann Whitney test using the Euclidean distance measurement. The clustering analysis revealed
classifiers for recurrent tumors (A) and all tumors (B). K-means clustering (K = 10; Euclidean distance) was also carried out with the distinct
clusters of immune response genes up regulated in non recurrent tumors (C) and HBA/HBB clusters down regulated in recurrent tumors (D).
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Table 4
Receiver operating curve and regression analysis of the markers
ROC analysis
Test result Area Std error Asymptotic 95 % p value
variable confidence Interval
Lower bound Upper bound
COL5A1 0.806 0.0793 0.650 0.961 0.0001
IGLA 0.824 0.0822 0.622 0.985 0.0001
HBB 0.975 0.0201 0.936 1.000 < 0.0001
CTSC 0.746 0.0914 0.566 0.925 0.0072
ABCG1 0.661 0.101 0.462 0.859 0.112
MMP1 0.533 0.109 0.319 0.748 0.759
EMP1 0.464 0.11 0.249 0.679 0.745
CCL18 0.605 0.109 0.392 0.818 0.334
Regression Analysis
Independent Coefficient Std. Error t p
variables
(Constant) −0.02586
COL5A1 0.33410 0.108 3.092 0.0046
HBB 0.67240 0.1088 6.182 < 0.0001
ples identified 244 probes with specific clusters of tran-
scription factors, regulatory proteins kinases (ZMYM2,
SFRS12, HIPK1, RNF12), stem cell associated factors
(ANKRD50, ATR) and hemoglobin genes that classified
them into recurrent and non-recurrent groups (Fig. 2A,
B & C). Statistical analysis also identified a set of 11
probes that overlapped between the adjacent mucosa
and tumor tissue of the recurrent sample set (Fig. 2D).
The ingenuity pathway analysis was carried out in
all groups; with p < 0.05 and Fishers exact test applied
as a test of significance. The top 10 canonical path-
ways identified in the recurrent and the non-recurrent
groups after core comparison analysis are represent-
ed in Figs 3A and 3B. The most significant pathways
include Glioma invasiveness signaling, bladder cancer
signaling, LXR/RXR activation and colorectal cancer
metastasis signaling in the recurrent group. The non-
recurrent set primarily showed Interferon signaling;
Cytotoxic T-lymphocyte mediated apoptosis of target
cells, protein ubiquitination and Myc mediated apopto-
sis as significant pathways. The recurrent profile was
characteristic in the absence of these immune response
pathways. Network analysis of the differentially ex-
pressed genes between the recurrent and non recurrent
tumor samples identified two primary interaction net-
workswhich showed differential regulation of the target
genes of XBP1 and E2F, genes of the troponin family
and the interacting partners HBB and HBA1 (Figs 4A
and 4B).
3.3. Validation of markers
Validationwas carried out for 8 genes, selected based
on their p-values and clustering ability in all the three
study groups. Quantification of the markers was car-
ried out by normalizing their expression to that of the
endogenous control (GAPDH) and relative to the ex-
pression in the normal mucosa samples (non-diseased
controls) using the ΔΔCT method. The expression
profile of fourmarkersCOL5A1, IGLA,HBB andCTSC
could differentiate between the three study groups, the
pattern being similar between the Group II & III sam-
ples (Fig. 5A). Analysis using the Receiver Operating
Curve Characteristics (ROC), revealed best empirical
area under curve (AUC) for these fourmarkers (Fig. 5B,
Table 4) with HBB providing the best predictive pow-
er (AUC 0.975; 95% CI 0.936–1.000, p =< 0.0001).
COL5A1 (p = 0.004) and HBB (p = 0.0001) had best
predictive power in combination as revealed by multi-
ple regression analysis (Table 4).
Among the 37 saliva samples analyzed,28 (Normals:
8; T1/T2: 20) were positive for the endogenous con-
trols byReverse TranscriptionPCR (RT PCR) andwere
hence selected for further analysis by quantitative PCR.
The expression of the markers was calculated with the
normal samples as the calibrator. Sixty-five percent
of (13/20) T1/T2 showed expression of one or more
of these markers (Fig. 5C). ABCG1, MMP1, COL5A1,
IL1B, IL8 and FN1 were detected in the tumors. IL1B
expression was observed in the normal samples, IGLA
was detected in only one tumor sample while FAPA,
HBB and SERPINH2 were undetected. ROC analysis
of the markers in combination (ABCG1, MMP1, FN1,
COL5A1, IL8), wherein detection of one or more of
the marker was considered a positive outcome) could
detect the patients with T1/T2 carcinoma with a sen-
sitivity of 0.65 and specificity of 0.87 (AUC: 0.762)
(Fig. 5D).
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Fig. 2. Differential expression in the adjacent mucosal tissue. Hierarchical clustering between adjacent mucosal tissue revealed extensive
differences in expression profiling (A). K-means clustering showed the up regulation of a sub-set of genes including stem cell genes such as
ATR, ARHGAP5 (B) and down regulation HBB/HBA1 cluster in the recurrent patients (C). Statistical analysis (ANOVA) also revealed a sub set
of genes overlapping between the adjacent mucosal tissue and tumor samples of the recurrent patients (D).
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Fig. 3. Significant pathways between Non-recurrent and recurrent tongue cancer. Pathway analysis was carried out by Ingenuity Pathway
Analysis (IPA) and the top 10 significant pathways are represented in the figure. The pathways are sorted according to significance in recurrent
sub set (A) and non-recurrent samples (B).
Immunohistochemical analysis of two of the mark-
ers, COL5A1 and HBB, showed a grade III-IV
COL5A1 (intense staining) and grade I-II HBB (mild
staining) in the patients of Group III (Fig. 6A) re-
spectively. ROC curve analysis showed that HBB
protein expression pattern could predict the resis-
tance/responsive behavior of the Group I and II patients
with a sensitivity of 0.84 and a specificity of 0.81 (AUC
of 0.870) (Figs 6B & C).
4. Discussion
Tongue cancer is one of the most invasive and ag-
gressive of cancers that occur in the oral cavity, with a
high risk of loco-regional failure as compared to other
sub-sites. Predicting resistance/response to treatment
is vital in order to devise personalized protocols for pa-
tients and in this context, the ability of molecular mark-
ers to improve the prognostication provided by the cur-
rent staging system gains significance. A set of highly
specific and sensitive molecular markers that detect the
small percentage of cells that are treatment resistant
will be a step towards accurate prognosis. These resis-
tant cells are enriched in the post treatment recurrent
tissue due to the significant reduction in the sensitive
cells as per the ‘log kill effect’. Our study attempts to
identify markers that specify these resistant cells and
focuses on evaluating their efficacy in treatment out-
come prediction and their utility as salivary markers.
Expression profiling using the Affymetrix system
and other platforms have documented the transcriptome
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Fig. 4. Interaction networks identified by Ingenuity Pathway Analysis. Interaction network of genes that are differentially expressed between
Non-recurrent and recurrent tumors (A & B). The symbols in the figure denote the following A: Activation, E: Expression, PP: protein-Protein
Interaction, I: Inhibition, L: Proteolysis; P: Phosphorylation, T: Transcription, PD: Protein-DNA interaction. Note the group of genes, the
expression of which is dependent upon XBP1 and E2F (A). The binding partners HBB and HBA1 are both higher in expression in non-recurrent
tumors (B).
Fig. 5. Validation in tissues and saliva samples. The expression profile of a select subset of markers was validated in tongue cancer specimens
(A). A distinct difference in expression profile of 4 genes (COL5A1, IGLA, HBB, and CTSC) was observed in the primary tissue of patients that
were non-recurrent (Group I) and recurrent (Group II). The pattern of expression obtained in the patients of the latter group was similar to that
obtained in the recurrent tissue of patients (Group III). ROC analysis revealed these markers as most significant according to the AUC (B). The
profile of 6 genes in saliva samples from normal (N) and tumor (T) samples is shown (C). The normal samples primarily show the expression of
IL1B while at least one of the carcinogenesis related genes are expressed in the patients. ROC analysis of the combination of markers (ABCG1,
IL8, COL5A1, FN1, and MMP1) shows sensitivity of 0.65 and specificity of 0.87 (D).
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Fig. 6. Immunohistochemical analysis of candidate markers. IHC was carried out on tongue cancer samples (A) with antibodies to HBB (a, b,
c, d) and COL5A1 (e, f, g, h). The expression was analyzed in normal controls (a, e), in non-recurrent tumor samples (b & f) and in recurrent
samples (c & g). d & h represent negative controls. The non-recurrent tumor sample showed a high expression of HBB as observed in the normal
control; while an over expression of COL5A1 was observed in the recurrent tumor sample. The magnifications (100 or 200 times the original
magnification) are mentioned on each panel. ROC analysis showed HBB as a better candidate marker as compared to COL5A1 (B & C).
pattern of head and neck squamous cell carcinoma in
general [16,17], tongue cancer in particular [18,19] and
its metastatic/recurrent forms [20]. MMPs, specifically
MMP1, which showed the highest fold level elevation in
both recurrent and non-recurrent tongue tumors in this
study, has been reported as significant in oral tumorige-
nesis previously [21,22]. Ginos et al. have previously
reported an absence of immune signature in recurrent
head and neck cancer patients [23]; a similar pattern is
observed in this study as revealed by the IPA analysis.
A significant up regulation of pathways associated with
immune response such as Interferon signaling, Cyto-
toxic T lymphocytemediated apoptosis and Oncostatin
M signaling was observed in the non-recurrent tumors.
Previous studies have reported these pathways to be as-
sociated with relapse free survival in breast cancers and
in adoptive immune therapy [24,25]. Network analy-
sis of the differentially expressed genes between non
recurrent and recurrent tumors, identified the troponin
family (TNNT, TNNC), as up regulated in the former, of
which Troponin 1 is a known angiogenic inhibitor [26].
CCNE1, identified previously as a marker of poor re-
sponse to treatment [27], was down regulated in these
tumors. The analyses also revealed a dysregulation of
the hemoglobingenes (HBB,HBA1, andHBA2) and the
targets of XBP1 such as PRDM1, SEC23B, previously
identified as differentially expressed in chemoresistant
leukemias, lymphomas and pancreatic cancers [28–30].
NFAT5 and ENAH, reported as involved in invasion and
metastasis during carcinogenesis were down regulated
in the non recurrent tumors [31–33].
The adjacent mucosa of the non-recurrent and recur-
rent groups showed a differential expression; probably
indicating the effect of field cancerization. The mucosa
from the recurrent subgroup showed a distinct induction
of a group of transcription factors, Zinc finger proteins
and regulatory proteins. Among the markers identified,
ZMYM2 (ZincfingerMYMtype-2) has been reported as
an early indicator of carcinogenesis in adjacent mucosa
of colorectal cancer and SFRS12 (splicing regulatory
glutamine/lysine-rich protein) in its progression [34,
35]. A subset of genes with known expression in ep-
ithelial and embryonic stem cells was also induced in
adjacent mucosa of recurrent tumors (ATR, ARHGAP5,
and ANKRD50). Ataxia telangiectasia mutated and
Rad3-related (ATR) promotes cell cycle progression in
the presence of double stranded DNA breaks [36]. A
loss in its activity enhances chemo sensitivity and re-
duces cancer cell survival [37], while a knockdown in
mice reduces the number and renewal/homeostatic ca-
pacity of the tissue-specific stem cells [38]. Ankyrin
repeat domain 50 (ANKRD50) and Rho GTPase Ac-
tivating protein 5 (ARHGAP5) are upregulated in epi-
dermal stem cells and neural progenitor cells respec-
tively [39,40]. The over expression of these markers
in the adjacent mucosal tissue of the resistant tumor
set in this study, supports the field cancerization con-
cept and attributes the ineffectiveness of therapy and
the subsequent loco-regional recurrence of the disease
to the residual and resistant stem cell-like population.
This also demonstrates that histologically negative ad-
jacent mucosal tissue may have undergone molecular
changes. Consequently, the validation of the markers
identified by the micro array platform in this study was
carried out using normal oral mucosa as controls.
Among the genes selected for validation, COL5A1,
HBB,CTSC and IGLA showed an expression profile
specific to the resistant tumors. COL5A1, a determi-
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nant of the stromal component of the tumor is known
to contribute to the carcinogenic and metastatic pro-
cesses as inferred by previous studies [41]. HBB has
been attributed with tumor suppressor activities and is
also designated as a survival factor in a number of can-
cers. Loss of Heterozygosity (LOH) of the HBB locus
(11p15.5) has been reported in lung, breast and ovar-
ian cancers [42–44]. Reduced HBB expression is ob-
served in lung adenocarcinomas [45] and is associated
with poor prognosis in non-small cell lung cancer [46].
Anaplastic thyroid cancer cell lines/tissues show a re-
pression of HBB, while its exogenous expression in cell
lines is known to lead to suppression of growth [47].
IgLA, the immune response gene, was over expressed
in the tumors that responded to treatment in this study.
Although this expression profile might be indicative of
other conditions (tissue differences, disease status), the
presence of a healthy immune response may indeed be
indicative of a better prognosis as reported in cancers
of the breast and head and neck [23,48]. Cathepsin C
(CTSC), a cysteine protease that functions in terminal
protein degradation and facilitates invasive growth, is
also validated in this study and has been previously re-
ported as up regulated in solid tumors [49]. The pattern
of expression of these validated genes was similar be-
tween primary tumor samples collected from patients
who developed recurrence during the follow-up peri-
od (Group II), and recurrent tumor specimens (Group
III), indicating that an accurate prognosis of treatment
response can be arrived at based on the primary tumor
signature.
MMP1, EMP1, CCL18 and ABCG1 were among the
genes that could not discriminate between the different
study groups in the validation cohort. MMP1 has been
identified as a possible marker of progression in ovar-
ian carcinomas and SNPs in the gene were associated
with treatment response in ovarian and lung cancer [50,
51], while EMP1, CCL18 and ABCG1 are reported to
be differentially regulated in solid tumors such as head
and neck and cervix [16,52–54] previously. However,
in this study, though the expression profile was distinct
in the tumor samples (both recurrent and non recurrent)
as compared to the adjacent mucosa, the patterns ob-
tained were not conclusive in discriminating the recur-
rent subset of patients. ABCG1 was over expressed in
the recurrent tumor set but the profile in the untreated
primary was not predictive of treatment response.
Expression profiling of tissue biomarkers in saliva
enables us to evaluate their efficacy in salivary diag-
nostics. RNA integrity was ensured by expression of
the endogenous control; 75% of the samples thus qual-
ified for analysis. A subset of the markers identified as
differentially expressed in oral cancer and its recurrent
formwere detected in the cell-free saliva of tongue can-
cer patients. Among these genes, IL8 and IL1B have
been previously identified as significant in oral cancer
patients [8] The relatively higher expression of IL1B in
the non-cancerous controls can be attributed to the fact
that its expression can also be induced by inflammatory
conditions [55]. This further emphasizes that the use
of a panel of markers improves the efficacy of the di-
agnosis. The expression of only a subset of the tumor
markers in saliva indicates that the genes differentially
expressed in tumors need to be screened thoroughly
to enable their application in salivary diagnostics. A
prospective study in a larger cohort of patients is cur-
rently ongoing in the laboratory to establish the clinical
relevance of the expression of the markers specific to
resistance/response (COL5A1) in saliva.
Identification of a set of markers that would predict
oral tongue tumors resistant to treatmentmodalities and
hence susceptible for recurrent behavior will have sig-
nificant clinical benefit. Our study provides evidence
that a specific panel of markers is indeed effective in
predicting recurrence, their detection in saliva suggest-
ing that further exploration of salivary markers in prog-
nostics may provide concrete results. Further expres-
sion studies in tissues from patients and their corre-
sponding saliva samples are warranted to identify new
candidate biomarkers which would increase the sensi-
tivity and specificity of treatment outcome prediction.
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